Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Heron Therapeutics, the most common co-covered peer. earnings accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. The tracked stories average 3 original sources each.
2 verified stories tracked
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Heron Therapeutics, the most common co-covered peer. earnings accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. The tracked stories average 3 original sources each. ZYNRELEF appears in 2 tracked Cross-Sector stories published from February 25, 2026 through February 26, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ZYNRELEF. Shared-story counts are live from our verified record — not editorial picks.
Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for 2025, characterized by revenue growth offset by margin pressures. Crucially, both firms took the rare step of introducing fiscal year 2026 guidance, signaling a strategic shift toward long-term stability in the radiopharmaceutical and acute care markets.
As the Q4 2025 earnings season commences, Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings are under intense scrutiny regarding their commercial execution and path to profitability. Investors are particularly focused on Delcath's HEPZATO KIT rollout and Lantheus's ability to maintain its dominance in the competitive radiopharmaceutical market.
